Celimmune and Celiac Disease Foundation Partner for Phase 2 Clinical Drug Study
Celimmune and Celiac Disease Foundation have joined forces to deploy the iCureCeliac patient registry as a screen for phase 2 clinical study for refractory celiac disease type II. This will be the first-ever use of the new and growing iCureCeliac
